Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiparametric analysis of vaccine-induced B and T cell responses for optimal evaluation of memory immune responses to Bordetella pertussis in children.

Vaccine·2026
Same author

Optimal Detection of Latent Mycobacterium tuberculosis Infection by Combined Heparin-Binding Hemagglutinin (HBHA) and Early Secreted Antigenic Target 6 (ESAT-6) Whole-Blood Interferon Gamma Release Assays.

Journal of clinical microbiology·2022
Same author

Tracheoesophageal fistula and pharyngoesophageal stenosis repair by double skin paddle radial forearm flap.

European annals of otorhinolaryngology, head and neck diseases·2021
Same author

Good old BCG - what a century-old vaccine can contribute to modern medicine.

Journal of internal medicine·2020
Same author

Live pertussis vaccines: will they protect against carriage and spread of pertussis?

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2017
Same author

In search of acceptable alternatives to the murine histamine sensitisation test (HIST): what is possible and practical?

Pharmeuropa bio & scientific notes·2017

Related Experiment Video

Updated: Jun 1, 2026

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis
06:26

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Published on: July 28, 2023

[New antituberculosis vaccines].

C Locht1, C Rouanet

  • 1Inserm 1019, centre d'infection et immunité de Lille, CNRS UMR9204, université Lille Nord de France, institut Pasteur de Lille, 1, rue du Professeur-Calmette, 59019 Lille cedex, France. camille.locht@pasteur-lille.fr

Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie
|June 17, 2011
PubMed
Summary
This summary is machine-generated.

New tuberculosis vaccines are urgently needed due to inconsistent efficacy of the current Bacille Calmette-Guérin (BCG) vaccine. Research focuses on improving BCG or developing novel prime-boost strategies.

More Related Videos

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

Related Experiment Videos

Last Updated: Jun 1, 2026

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis
06:26

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Published on: July 28, 2023

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

Area of Science:

  • Infectious Diseases
  • Vaccinology
  • Microbiology

Context:

  • Tuberculosis (TB) remains a global health challenge, with the existing Bacille Calmette-Guérin (BCG) vaccine showing highly variable efficacy.
  • BCG, developed a century ago, has been administered over 3 billion times but its effectiveness against TB varies significantly across studies.
  • Booster vaccinations with BCG have not improved its efficacy, highlighting the need for novel vaccine approaches.

Purpose:

  • To review current research efforts aimed at developing new and improved vaccines against tuberculosis.
  • To explore strategies for overcoming the limitations of the current BCG vaccine.
  • To summarize the progress in developing alternative TB vaccines and prime-boost strategies.

Summary:

  • Current research pursues two main strategies: replacing BCG with superior vaccines (e.g., improved BCG strains or genetically attenuated *Mycobacterium tuberculosis*) or employing heterologous prime-boost strategies using BCG followed by specific antigens.
  • These novel approaches, including the use of latency antigens in prime-boost regimens, have shown promising results in preclinical animal models.
  • Several of these new vaccine candidates have advanced to clinical trials, indicating significant progress in the field.

Impact:

  • Development of more effective tuberculosis vaccines could significantly reduce the global burden of this infectious disease.
  • Improved TB vaccines may offer better protection, particularly in diverse populations where BCG efficacy is suboptimal.
  • Advancements in TB vaccinology are crucial for controlling and potentially eradicating tuberculosis worldwide.